earnings
CV
NASDAQ · CVKD
Cadrenal Therapeutics, Inc. Common Stock
Healthcare · Biotechnology
$1.08
Up+$0.04 (+3.70%)
Updated Sep 17, 2026, 9:52 PM
SID Score
3.7/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 22.83M
- P/E ratio
- -1.56
- Dividend yield
- 0.00%
- 52-week range
- $1.00 – $8.35
- Volume
- 56.33K
- Avg. volume
- 27.14K
Price performance
CVKD price history
1M range · 20 trading sessions · Daily adjusted prices
CVKD closed at $1.08 after 20 trading sessions, down 34.15% for the selected period.
- Last close
- $1.08
- Period change
- -34.15%
- Period low
- $1.05
- Period high
- $1.75
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 16, 2026 | $1.05 | $1.10 | $1.01 | $1.08 | 56.33K |
| Sep 15, 2026 | $1.06 | $1.1199 | $1.04 | $1.05 | 56.4K |
| Sep 14, 2026 | $1.07 | $1.10 | $1.0542 | $1.06 | 49.75K |
| Sep 11, 2026 | $1.17 | $1.1889 | $1.00 | $1.09 | 229.8K |
| Sep 10, 2026 | $1.17 | $1.20 | $1.14 | $1.18 | 119.85K |
| Sep 9, 2026 | $1.22 | $1.23 | $1.14 | $1.19 | 114.67K |
| Sep 8, 2026 | $1.20 | $1.26 | $1.16 | $1.20 | 162.01K |
| Sep 4, 2026 | $1.26 | $1.295 | $1.20 | $1.22 | 180.82K |
| Sep 3, 2026 | $1.34 | $1.41 | $1.27 | $1.28 | 172.38K |
| Sep 2, 2026 | $1.40 | $1.53 | $1.28 | $1.33 | 394.39K |
| Sep 1, 2026 | $1.49 | $1.58 | $1.42 | $1.51 | 783.83K |
| Aug 31, 2026 | $1.64 | $2.29 | $1.46 | $1.75 | 21.6M |
| Aug 28, 2026 | $1.56 | $1.60 | $1.50 | $1.54 | 31.35K |
| Aug 27, 2026 | $1.52 | $1.6221 | $1.52 | $1.565 | 48.18K |
| Aug 26, 2026 | $1.56 | $1.6434 | $1.49 | $1.55 | 24.71K |
| Aug 25, 2026 | $1.56 | $1.61 | $1.50 | $1.53 | 39.22K |
| Aug 24, 2026 | $1.69 | $1.69 | $1.54 | $1.57 | 36.24K |
| Aug 21, 2026 | $1.62 | $1.62 | $1.541 | $1.61 | 36.25K |
| Aug 20, 2026 | $1.65 | $1.725 | $1.58 | $1.59 | 59.97K |
| Aug 19, 2026 | $1.75 | $1.775 | $1.62 | $1.64 | 81K |
Latest CVKD news
The latest Smart Investors Daily articles mentioning CVKD.
Stock researchResearch & News · SID Coverage
Loading stock research…

